A resting electrocardiogram (EKG) with a corrected QT (QTC) >= 470 msec detected on 2 or more time points within a 2 hour period or family history of long QT syndrome; if the EKG demonstrates QTC >= 470 msec, the patient will only be eligible if a repeat EKG demonstrates QTC =< 470 msec
No supraventricular arrhythmia on electrocardiogram (EKG)
Adequate cardiac function, defined as:\r\n* No electrocardiogram (EKG) evidence of acute ischemia\r\n* No EKG evidence of active, clinically significant conduction system abnormalities\r\n* No EKG evidence of > grade 2 (> 480 ms) corrected QT (QTc) prolongation \r\n* Prior to study entry, any EKG abnormality at screening not felt to put the patient at risk has to be documented by the investigator as not medically significant\r\n* No uncontrolled angina or severe ventricular arrhythmias\r\n* No clinically significant pericardial disease\r\n* No history of myocardial infarction within 6 months prior to registration\r\n* No class 3 or higher New York Heart Association congestive heart failure
Patients must have QTcF (by Fridericia calculation) < 480/msec based on electrocardiogram (EKG) performed within 28 days prior to registration
Patients must not have a screening corrected QT using Fridericia's formula (QTcF) interval > 500 milliseconds (by Fridericia calculation) based on the average of triplicate electrocardiogram (EKG) performed within 7 days prior to registration; note that triplicate EKG is required at other time points
Resting electrocardiography (EKG) with corrected QT (QTc) > 470 msec or family history of long QT syndrome; if EKG demonstrates QTc > 470 msec, patient will be eligible only if repeat EKG demonstrates QTc ? 470 msec
Patients who have ongoing cardiac dysrhythmias, atrial fibrillation, or prolongation of corrected QTc interval to > 480 msec on 2 out of 3 electrocardiograms (EKGs) (if first EKG has QTc < 480, no need to repeat, if first EKG has QTc > 480 repeat twice for a total of 3 EKGs)
Patients may not have any clinically significant cardiovascular disease including the following:\r\n* Myocardial infarction or ventricular tachyarrhythmia within 6 months\r\n* Major conduction abnormality (unless a cardiac pacemaker is present)\r\n* Patients with any cardiopulmonary symptoms of unknown cause (e.g., shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out corrected QT (QTc) prolongation; the patient may be referred to a cardiologist at the discretion of the principal investigator; patients with underlying cardiopulmonary dysfunction should be excluded from the study
TREATMENT INCLUSION: Electrocardiography (EKG) shows no significant arrhythmias
Fridericia’s corrected QT (QTcF) value of =< 470 msec on screening electrocardiogram (EKG) within 14 days prior to start of protocol therapy.
Electrocardiogram (EKG) documenting corrected QT (QTc) interval < 480 mili (m)second and no clinically significant arrhythmia
QTcF (Fridericia Correction Formula) > 480 on 2 out of 3 EKG’s (if first EKG is =< 480, no need to repeat, if first electrocardiogram [EKG] is > 480 repeat twice for a total of 3 EKG’s)
TREATMENT WITH SJCAR19: Electrocardiogram (EKG) without evidence of clinically significant arrhythmia
Abnormal electrocardiogram (EKG) (study physician discretion)
Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%
Baseline electrocardiogram (EKG) shows corrected QT interval by Fredericia (QTcF) > 470 msec.
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Patients with electrocardiogram (EKG) within 14 days of initiation of chemotherapy demonstrating no new significant rhythm, axis or ST segment changes will be included; if clinically significant, new EKG changes are present, patients may be included if cardiac stress test indicates no reversible cardiac ischemia
Patients must not have corrected QT (QTc)F (Fridericia Correction Formula) > 480 on 2 out of 3 electrocardiograms (EKG’s) (if first EKG is =< 480, no need to repeat, if first EKG is > 480 repeat twice for a total of 3 EKG’s)
Electrocardiogram (EKG) with QTcB (Bazett’s formula) > 480 ms done within 14 days of enrollment
Electrocardiogram (EKG) showing no ischemic changes and no abnormal rhythm
Adequate cardiac function as demonstrated by electrocardiogram (EKG) and/or echocardiographic evidence (may be performed within 30 days prior to treatment)
Fridericia corrected QT (QTcF) interval on the electrocardiogram (EKG) greater than 480 milliseconds
Electrocardiogram (EKG) without clinically significant abnormality
Normal EKG and LVEF >40%, measured by EKG and MUGA scan, radionuclide ventriculogram, or echocardiogram
Pretreatment electrocardiography (EKG).
Corrected QT interval less than 500 milliseconds by electrocardiogram (EKG)
Patients must have undergone an electrocardiogram (EKG) within 28 days prior to registration
Patients with electrocardiogram (EKG) within 14 days of initiation of chemotherapy demonstrating no new rhythm, axis or ST segment changes will be included; if clinically significant, new EKG changes are present, patients may be included if cardiac stress test indicates no cardiac ischemia
QTc prolongation defined as a QTc interval >= 480 msecs or other significant electrocardiogram (EKG) abnormalities are ineligible; Note: if unsure about EKG abnormality, the treating physician should discuss this with Drs. Sherman or Bible
Electrocardiogram (EKG) within 8 weeks of registration
Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 7 days prior to registration
Corrected QTc interval > 480 msec; baseline electrocardiogram (EKG) obtained pre-transplant does not need to be repeated unless clinically indicated
Corrected QT interval (QTc) > 470 milliseconds (msec) on a 12-lead electrocardiography (EKG) obtained during the screening period; if a machine reading is above this value, the EKG should be reviewed by a qualified reader and confirmed on a subsequent EKG
Patients with baseline corrected QT (QTc) prolongation greater than grade 1 are excluded from this study; patients with grade 1 QTc elevation are eligible but must be monitored with electrocardiogram (ECG) (EKG) exams, for the first 3 cycles of treatment; eribulin time to maximum concentration (Cmax) after infusion is about 10 minutes, and half life is 40 minutes; ECG (EKG) should be performed between 10 to 40 minutes after eribulin administration (on day 1 and day 8 of treatment); continued ECG (EKG) monitoring beyond cycle 3 can be done at the discretion of the treating physician
Patients will be required to have a baseline electrocardiogram (EKG) prior to the start of treatment; patients with a corrected QT (QTc) > 480 millisecond (ms) are excluded from the study
Corrected QT interval less than 500 milliseconds by electrocardiogram (EKG)
Abnormal electrocardiogram (EKG): severe uncontrolled ventricular arrhythmias, or evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any EKG abnormality at screening has to be documented by the investigator as not medically relevant
For patients on mefloquine arm, a baseline electrocardiogram (EKG) without evidence of prolonged corrected QT (QTc) interval > 450 ms or clinically significant arrhythmia must be obtained within 14 days prior to registration
For mefloquine arm, patients with evidence of QTc interval > 450 ms or clinically significant arrhythmia on baseline EKG obtained within 14 days of registration will be ineligible for protocol enrollment
Patients must not have any clinically significant cardiovascular disease including the following: myocardial infarction or ventricular tachyarrhythmia within 6 months, prolonged corrected QT interval (QTc) > 480 msec (Fridericia correction), ejection fraction less than institutional normal, major conduction abnormality (unless a cardiac pacemaker is present); patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) are to be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation; the patient may be referred to a cardiologist at the discretion of the principal investigator; patients with underlying cardiopulmonary dysfunction are excluded from the study
Patients must have an electrocardiogram (EKG) that shows no significant abnormalities that are suggestive of active cardiac disease
Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation; the patient may be referred to a cardiologist at the discretion of the treating physician; patients with underlying cardiopulmonary dysfunction should be excluded from the study
Donor has a chest x-ray (CXR) and electrocardiogram (EKG) performed
Participants with a QTcF (Fridericia correction formula) > 480 ms on 2 out of 3 electrocardiograms (EKGs) (if first EKG is < 480, no need to repeat, if first EKG is > 480 repeat twice for a total of 3 EKGs)
Patients must have an electrocardiogram (EKG) documenting normal intervals (especially QTc interval < 480 msec) and no arrhythmia prior to enrollment
Electrocardiogram (EKG) abnormalities of:\r\n* Q-wave infarction, unless identified 6 or more months prior to screening\r\n* QTc interval > 470 msec, the upper limit of normal for women
Patients must have an electrocardiogram (EKG) with no significant abnormalities within 28 days prior to registration
Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 14 days prior to registration
Q-T interval of =< 450 ms as measured by electrocardiography (EKG)
A history of clinically significant electrocardiogram (EKG) abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) less than 1 year ago with ensuing unstable EKG
Electrocardiogram (EKG), vitals and laboratory values outside of normal limits at the time of enrollment, unless these are deemed not clinically significant by clinician
New (< 6 months) cardiac arrhythmia (electrocardiogram [EKG] should be performed within 2 weeks of starting IFN gamma)
